Physician profile
Norman E Ferrer
NPI 1750492393
$1,260.77
in general payments reported to CMS, 2019-2025
24 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $66.84 · 2021: $17.41 · 2022: $245 · 2023: $245 · 2024: $335 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $771.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $178.53 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.57 | 2024 | Xifaxan |
| Organon LLC | $117.53 | 2022-2024 | Nexplanon |
| Caldera Medical, INC | $80.08 | 2022 | |
| Coopersurgical, INC. | $78.46 | 2020-2025 | Paragard T 380a, Paragard T 380a |
| Biogen, INC. | $78.25 | 2023-2024 | Zurzuvae, Spinraza |
| Astellas Pharma US INC | $72.27 | 2020-2025 | Veozah |
| Sumitomo Pharma America, INC. | $71.40 | 2024-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $68.40 | 2022-2025 | |
| Octapharma USA, INC. | $55.93 | 2025 | Fibryga |
| Pfizer INC. | $42.60 | 2022-2023 | |
| Medtronic, INC. | $36.62 | 2023 | Ligasure |
| Exeltis, USA INC. | $35.05 | 2023-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $30.32 | 2019 | |
| Hologic Sales and Service, LLC | $17.41 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $16.05 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $15.58 | 2019 | |
| Novo Nordisk INC | $14.56 | 2023 | Wegovy |
| Merck Sharp & Dohme LLC | $14.39 | 2022 | |
| Lupin INC. | $13.16 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $12.97 | 2023 | Exparel |
| Acacia Pharma INC | $12.54 | 2022 | |
| Amag Pharmaceuticals, INC. | $12.09 | 2019 | |
| Duchesnay USA Incorporated | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Ferrer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.